Shares of Gilead Sciences Inc. (NASDAQ:GILD) were up 1.8% on Friday . The company traded as high as $87.96 and last traded at $87.07, with a volume of 7,670,166 shares. The stock had previously closed at $85.54.

A number of analysts have recently weighed in on GILD shares. Royal Bank Of Canada restated a “buy” rating on shares of Gilead Sciences in a report on Wednesday, March 23rd. Jefferies Group restated a “hold” rating and issued a $96.00 target price on shares of Gilead Sciences in a report on Friday, May 27th. JPMorgan Chase & Co. restated a “buy” rating on shares of Gilead Sciences in a report on Saturday, May 14th. Morgan Stanley restated a “hold” rating and issued a $103.00 target price on shares of Gilead Sciences in a report on Wednesday, June 15th. Finally, Robert W. Baird restated an “outperform” rating and issued a $135.00 target price on shares of Gilead Sciences in a report on Monday, June 6th. Eight investment analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and an average target price of $114.05.

The firm has a 50 day moving average of $84.60 and a 200 day moving average of $89.46. The firm has a market capitalization of $115.43 billion and a PE ratio of 7.40.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $3.03 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.13 by $0.10. The firm had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $8.08 billion. During the same quarter in the prior year, the company posted $2.94 earnings per share. The company’s quarterly revenue was up 2.6% on a year-over-year basis. Equities analysts expect that Gilead Sciences Inc. will post $12.05 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 29th. Shareholders of record on Thursday, June 16th were paid a dividend of $0.47 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 2.17%. The ex-dividend date of this dividend was Tuesday, June 14th.

In other Gilead Sciences news, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction dated Tuesday, April 19th. The shares were sold at an average price of $100.01, for a total transaction of $4,000,400.00. Following the transaction, the executive vice president now directly owns 177,964 shares of the company’s stock, valued at $17,798,179.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $83.12, for a total transaction of $166,240.00. Following the transaction, the executive vice president now directly owns 63,122 shares in the company, valued at $5,246,700.64. The disclosure for this sale can be found here.

A number of institutional investors have recently modified their holdings of GILD. Sfmg LLC increased its position in shares of Gilead Sciences by 5.2% in the fourth quarter. Sfmg LLC now owns 10,619 shares of the biopharmaceutical company’s stock worth $1,075,000 after buying an additional 522 shares during the period. NEXT Financial Group Inc increased its position in shares of Gilead Sciences by 1.7% in the fourth quarter. NEXT Financial Group Inc now owns 10,889 shares of the biopharmaceutical company’s stock worth $1,101,000 after buying an additional 183 shares during the period. Parsec Financial Management Inc. increased its position in shares of Gilead Sciences by 121.1% in the fourth quarter. Parsec Financial Management Inc. now owns 10,905 shares of the biopharmaceutical company’s stock worth $1,103,000 after buying an additional 5,972 shares during the period. Farmers & Merchants Investments Inc. increased its position in shares of Gilead Sciences by 8,897.6% in the fourth quarter. Farmers & Merchants Investments Inc. now owns 11,337 shares of the biopharmaceutical company’s stock worth $1,147,000 after buying an additional 11,211 shares during the period. Finally, Baxter Bros Inc. increased its position in shares of Gilead Sciences by 42.1% in the fourth quarter. Baxter Bros Inc. now owns 11,798 shares of the biopharmaceutical company’s stock worth $1,194,000 after buying an additional 3,493 shares during the period.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.